1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Gilead Sciences, Inc.US flagNASDAQ Global Select
151.00
USD
-0.22
- -
187.47BMarket Cap

Total Valuation

Gilead Sciences, Inc. carries a market capitalization of 187.47B, placing it among publicly traded companies globally. Its enterprise value stands at 179.77B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap187.47B
Enterprise Value179.77B

Share Statistics

Gilead Sciences, Inc. currently has 1.24B shares outstanding.

Shares Outstanding1.24B
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Gilead Sciences, Inc. trades at a trailing price-to-earnings ratio of 75.42. The price-to-sales ratio is 5.15, and the price-to-book ratio stands at 13.26.

PE Ratio75.42
PS Ratio5.15
PB Ratio13.26
P/TBV Ratio-14.91
P/FCF Ratio11.16
P/OCF Ratio11.58

Enterprise Valuation

On an enterprise value basis, Gilead Sciences, Inc. trades at an EV/EBITDA multiple of 12.42 and an EV/FCF ratio of 11.37. The EV/Sales ratio of 5.90 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 15.34 provides insight into valuation relative to core operating earnings.

EV / Sales5.90
EV / EBITDA12.42
EV / EBIT15.34
EV / FCF11.37

Financial Position

Gilead Sciences, Inc. maintains a current ratio of 1.27, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 223.48, indicating elevated leverage, while an interest coverage ratio of 14.51 demonstrates strong ability to service its debt obligations.

Current Ratio1.27
Quick Ratio0.75
Debt / Equity223.48
Debt / EBITDA1.81
Interest Coverage14.51

Financial Efficiency

Gilead Sciences, Inc. posts a return on equity of -20.57 and a return on invested capital of 20.78.

Return on Equity (ROE)-20.57
Return on Assets (ROA)-6.17
Return on Invested Capital (ROIC)20.78
Return on Capital Employed (ROCE)40.57
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover3.29

Taxes

Over the trailing twelve months, Gilead Sciences, Inc. has paid 1.29B in income taxes, reflecting an effective tax rate of 37.84.

Income Tax1.29B
Effective Tax Rate37.84

Stock Price Statistics

Gilead Sciences, Inc.'s stock has gained approximately 33.89643% over the past 52 weeks. The 50-day moving average sits at 136.06, while the 200-day moving average is 134.23.

Beta (5Y)N/A
52-Week Price Change33.89643%
50-Day Moving Average136.06
200-Day Moving Average134.23
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Gilead Sciences, Inc. generated 30.46B in revenue and converted that into -3.24B in net income, yielding earnings per share of -2.59. EBITDA reached 14.48B, while operating income came in at 11.72B.

Revenue30.46B
Gross Profit24.24B
Operating Income11.72B
Pretax Income-1.95B
Net Income-3.24B
EBITDA14.48B
EBIT11.72B
Earnings Per Share (EPS)-2.59

Balance Sheet

Gilead Sciences, Inc. holds 3.18B in cash and equivalents against 26.25B in total debt, resulting in a net debt position of 23.07B. Total book value stands at 11.83B, with working capital of 2.93B providing operational flexibility.

Cash & Cash Equivalents3.18B
Total Debt26.25B
Net Debt23.07B
Equity (Book Value)11.83B
Book Value Per Share9.53
Working Capital2.93B

Cash Flow

Gilead Sciences, Inc. produced 13.55B in operating cash flow over the past twelve months. After subtracting -609.00M in capital expenditures, free cash flow totaled 12.94B - equivalent to 10.42 per share.

Operating Cash Flow13.55B
Capital Expenditures-609.00M
Free Cash Flow12.94B
FCF Per Share10.42

Margins

Gilead Sciences, Inc. operates with a gross margin of 79.59, reflecting its pricing power and cost economics. The operating margin of 38.47 and net profit margin of -10.64 provide insight into operational efficiency.

Gross Margin79.59
Operating Margin38.47
Pretax Margin-6.42
Profit Margin-10.64
EBITDA Margin47.53

Dividends & Yields

The company's payout ratio of -125.56 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share3.27
Dividend YieldN/A
Payout Ratio-125.56
Shareholder Yield2.96
FCF Yield8.96

Stock Splits

Gilead Sciences, Inc.'s most recent stock split took place on January 28, 2013 with a 1:2 split ratio.

Last Split Date1/28/2013
Split Ratio1:2

Scores

Gilead Sciences, Inc. posts an Altman Z-Score of 5.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.30